<?xml version="1.0" encoding="UTF-8"?>
<ref id="B10-biomedicines-08-00060">
 <label>10.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hauschild</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Grob</surname>
    <given-names>J.-J.</given-names>
   </name>
   <name>
    <surname>Demidov</surname>
    <given-names>L.V.</given-names>
   </name>
   <name>
    <surname>Jouary</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Gutzmer</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Millward</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Rutkowski</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Blank</surname>
    <given-names>C.U.</given-names>
   </name>
   <name>
    <surname>Miller</surname>
    <given-names>W.H.</given-names>
   </name>
   <name>
    <surname>Kaempgen</surname>
    <given-names>E.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial</article-title>
  <source>Lancet</source>
  <year>2012</year>
  <volume>380</volume>
  <fpage>358</fpage>
  <lpage>365</lpage>
  <pub-id pub-id-type="doi">10.1016/S0140-6736(12)60868-X</pub-id>
  <pub-id pub-id-type="pmid">22735384</pub-id>
 </element-citation>
</ref>
